Literature DB >> 16849465

CXCL16 influences the nature and specificity of CpG-induced immune activation.

Mayda Gursel1, Ihsan Gursel, Howard S Mostowski, Dennis M Klinman.   

Abstract

Unmethylated CpG motifs are present at high frequency in bacterial DNA. They provide a danger signal to the mammalian immune system that triggers a protective immune response characterized by the production of Th1 and proinflammatory cytokines and chemokines. Although the recognition of CpG DNA by B cells and plasmacytoid dendritic cells is mediated by TLR 9, these cell types differ in their ability to bind and respond to structurally distinct classes of CpG oligonucleotides. This work establishes that CXCL16, a membrane-bound scavenger receptor, influences the uptake, subcellular localization, and cytokine profile induced by D oligonucleotides. This is the first example of a surface receptor modifying the cellular specificity and nature of the immune response mediated by an intracellular TLR.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16849465     DOI: 10.4049/jimmunol.177.3.1575

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  Antimicrobial peptides inhibit polyinosinic-polycytidylic acid-induced immune responses.

Authors:  Maroof Hasan; Catarina Ruksznis; Yan Wang; Cynthia Anne Leifer
Journal:  J Immunol       Date:  2011-11-02       Impact factor: 5.422

2.  Activation of type I interferon-dependent genes characterizes the "core response" induced by CpG DNA.

Authors:  Folkert Steinhagen; Corinna Meyer; Debra Tross; Mayda Gursel; Takahiro Maeda; Sven Klaschik; Dennis M Klinman
Journal:  J Leukoc Biol       Date:  2012-07-02       Impact factor: 4.962

Review 3.  Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.

Authors:  Marcin Kortylewski; Dayson Moreira
Journal:  Cancer Immunol Immunother       Date:  2017-02-18       Impact factor: 6.968

Review 4.  Synthetic oligonucleotides as modulators of inflammation.

Authors:  Dennis Klinman; Hidekazu Shirota; Debra Tross; Takashi Sato; Sven Klaschik
Journal:  J Leukoc Biol       Date:  2008-04-22       Impact factor: 4.962

5.  The Toll-like receptor 9 signalling pathway regulates MR1-mediated bacterial antigen presentation in B cells.

Authors:  Jianyun Liu; Randy R Brutkiewicz
Journal:  Immunology       Date:  2017-06-29       Impact factor: 7.397

Review 6.  Traditional biochemical assays for studying toll-like receptor 9.

Authors:  Cynthia A Leifer; William A Rose; Fernando Botelho
Journal:  J Immunoassay Immunochem       Date:  2013

Review 7.  Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9.

Authors:  Petar S Lenert
Journal:  Mediators Inflamm       Date:  2010-05-18       Impact factor: 4.711

8.  Selective control of type I IFN induction by the Rac activator DOCK2 during TLR-mediated plasmacytoid dendritic cell activation.

Authors:  Kazuhito Gotoh; Yoshihiko Tanaka; Akihiko Nishikimi; Risa Nakamura; Hisakata Yamada; Naoyoshi Maeda; Takahiro Ishikawa; Katsuaki Hoshino; Takehito Uruno; Qinhong Cao; Sadayuki Higashi; Yasushi Kawaguchi; Munechika Enjoji; Ryoichi Takayanagi; Tsuneyasu Kaisho; Yasunobu Yoshikai; Yoshinori Fukui
Journal:  J Exp Med       Date:  2010-03-15       Impact factor: 14.307

9.  Plasmodium falciparum exposure in utero, maternal age and parity influence the innate activation of foetal antigen presenting cells.

Authors:  Nadine Fievet; Stefania Varani; Samad Ibitokou; Valérie Briand; Stéphanie Louis; René Xavier Perrin; Achille Massougbogji; Anne Hosmalin; Marita Troye-Blomberg; Philippe Deloron
Journal:  Malar J       Date:  2009-11-05       Impact factor: 2.979

10.  DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Fas(lpr/lpr) mice in vivo.

Authors:  Petar Lenert; Kei Yasuda; Liliana Busconi; Patrice Nelson; Courtney Fleenor; Radhika S Ratnabalasuriar; Peter L Nagy; Robert F Ashman; Ian R Rifkin; Ann Marshak-Rothstein
Journal:  Arthritis Res Ther       Date:  2009-05-28       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.